EC
SLRN

EntryPoint Capital’s ACELYRIN SLRN Stock Holding History

EntryPoint Capital’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,033
Closed -$74.5K – 1559
2024
Q1 		$74.5K Sell
11,033
-9,935
-47% -$75.5K 0.07% 569
2023
Q4 		$156K Buy
+20,968
New +$179K 0.15% 172

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

EntryPoint Capital's SLRN Position: Q2 2024 in Review

EntryPoint Capital sold out of ACELYRIN (SLRN) in Q2 2024, closing a stake of 11,033 shares — an estimated $74.5K sold.

EntryPoint Capital first reported a position in SLRN in Q4 2023 and held it in 2 quarters. The position peaked at $156K in Q4 2023. 112 funds tracked by Wall St. Rank hold SLRN as of Q2 2024.

  • EntryPoint Capital reported no remaining ACELYRIN position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 11,033 ACELYRIN shares in Q2 2024, an estimated $74.5K.
  • EntryPoint Capital first reported a position in ACELYRIN in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's ACELYRIN position peaked at $156K in Q4 2023.
  • 112 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.